Not an approved drug. Retatrutide is investigational — still in clinical trials, not FDA-approved. Any "retatrutide" sold as a research chemical is not the trial medicine and has no approved use. Educational only; not medical advice.
What it is
Retatrutide is a single peptide that agonizes three receptors: GIP, GLP-1, and glucagon. It extends the dual-agonist logic of tirzepatide by adding glucagon-receptor activity.
Mechanism — why add glucagon?
Counter-intuitively, agonizing the glucagon receptor (alongside the incretin receptors) is thought to increase energy expenditure and hepatic fat handling, while the GLP-1 component offsets glucagon's tendency to raise blood sugar. The combined design aims for larger weight effects than dual agonists.1 All three are class B GPCRs.2
Evidence caveat: the mechanism is well-reasoned and the early data striking, but this is a molecule still being tested — long-term efficacy and safety are not yet established.
State of the evidence
Phase 2 trials reported large weight reductions and generated significant attention; Phase 3 trials are ongoing. It is not approved anywhere. Track current trial status on ClinicalTrials.gov.3
Regulatory reality
Status: investigational; no approved product; not legally a medicine.
Gray-market powder: unverified "retatrutide" is neither the trial drug nor quality-controlled — the COA and evidence-tier caveats matter enormously here.
References
Triple-targeting to accelerate weight loss (Harvard HMS insight). learn.hms.harvard.edu
Kobilka, GPCR structure (2012 Nobel lecture/review). Angew. Chem.
For educational and research purposes only. This content is not medical advice. Compounds referenced are research use only and not intended to diagnose, treat, cure, or prevent any disease. Free Peptide University does not sell compounds.